DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Dalmane (Flurazepam Hydrochloride) - Summary

 
 



DALMANE SUMMARY

Dalmane is available as capsules containing 15 mg or 30 mg flurazepam hydrochloride.

Dalmane is a hypnotic agent useful for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakening. Dalmane can be used effectively in patients with recurring insomnia or poor sleeping habits, and in acute or chronic medical situations requiring restful sleep. Sleep laboratory studies have objectively determined that Dalmane is effective for at least 28 consecutive nights of drug administration. Since insomnia is ofter transient and intermittent, short-term use is usually sufficient. Prolonged use of hypnotics is usually not indicated and should only be undertaken concomitantly with appropriate evaluation of the patient.


See all Dalmane indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Dalmane (Flurazepam)

Online CBT Effective for Insomnia, Psychosis
Source: Medscape NeurologyHeadlines [2017.09.13]
Internet-based cognitive-behavioral therapy (CBT) not only improves insomnia but also appears to reduce paranoia and hallucinations.
Medscape Medical News

Online Insomnia Therapy Helps Improve Mental Health (CME/CE)
Source: MedPage Today Psychiatry [2017.09.06]
(MedPage Today) -- Digital CBT reduced insomnia, paranoia, hallucinations

20 Tips to Beat Insomnia and Sleep Better
Source: MedicineNet Sleep Aids And Stimulants Specialty [2017.07.26]
Title: 20 Tips to Beat Insomnia and Sleep Better
Category: Slideshows
Created: 10/1/2014 12:00:00 AM
Last Editorial Review: 7/26/2017 12:00:00 AM

Insomnia
Source: MedicineNet Hyperthyroidism Specialty [2017.05.12]
Title: Insomnia
Category: Symptoms and Signs
Created: 7/28/2006 12:00:00 AM
Last Editorial Review: 5/12/2017 12:00:00 AM

Insomnia (Symptoms, Causes, Remedies, and Cures)
Source: MedicineNet Biorhythms Specialty [2017.04.19]
Title: Insomnia (Symptoms, Causes, Remedies, and Cures)
Category: Diseases and Conditions
Created: 6/6/2005 12:00:00 AM
Last Editorial Review: 4/19/2017 12:00:00 AM

more news >>

Published Studies Related to Dalmane (Flurazepam)

A double-blind, placebo- and flurazepam-controlled investigation of the residual psychomotor and cognitive effects of modified release zolpidem in young healthy volunteers. [2006.06]
Short-acting hypnotic drugs, such as zolpidem, have minimal residual effects but may not provide optimal efficacy throughout the night for all insomnia patients... In conclusion, the study showed the good tolerance of zolpidem-MR in terms of residual neuropsychological effects as well as a beneficial effect on sleep quality in young healthy adults.

Effects of flurazepam and zolpidem on the perception of sleep in insomniacs. [1995.02]
We have shown previously that the benzodiazepine hypnotic triazolam alters the perception of being awake or asleep in insomniacs, making it more likely that they will report having been asleep when awakened by an electronic tone at various times of the night... These findings suggest that drug-induced alterations in the perception of being awake or asleep are not unique to benzodiazepines, but occur with the nonbenzodiazepine zolpidem as well.

Effects of estazolam and flurazepam on cardiopulmonary function in patients with chronic obstructive pulmonary disease. [1992.03]
Benzodiazepine drugs have been shown to suppress respiratory function in patients with chronic obstructive pulmonary disease (COPD). We designed a placebo-controlled crossover study to compare the effects of a new benzodiazepine, estazolam ('ProSom'), with those of flurazepam ('Dalmane') on cardiopulmonary function in COPD patients...

Objective measurements of daytime sleepiness and performance comparing quazepam with flurazepam in two adult populations using the Multiple Sleep Latency Test. [1991.09]
Daytime residual drowsiness and psychomotor performance were assessed for two long half-life benzodiazepines, quazepam and flurazepam, in two randomized, parallel, and double-blind studies in insomniacs... Thus, quazepam 15 mg produces less daytime somnolence and fewer psychomotor performance decrements than does flurazepam.

Hypnotic efficacy of estazolam compared with flurazepam in outpatients with insomnia. [1991.08]
Estazolam is a new benzodiazepine hypnotic agent with an intermediate half-life of 12 to 15 hours... Estazolam 1 mg is also effective in the treatment of outpatients with insomnia, but to a lesser degree.

more studies >>

Clinical Trials Related to Dalmane (Flurazepam)

Study to Evaluate the Effect of 2 Dosage Strengths of E2006 on a Multiple Sleep Latency Test in Subjects With Insomnia Disorder [Completed]
This is a single-dose, randomized, placebo-controlled, 3-way crossover study of 2 dosage strengths of E2006 (5 mg and 10 mg) in subjects with insomnia disorder.

Pharmacovigilance in Gerontopsychiatric Patients [Recruiting]
The purpose of this multicenter-study is to investigate safety of psychopharmacological treatment and rates of adverse drug reactions in gerontopsychiatric inpatients. Elderly people are at higher risk for developing side effects under pharmacological treatment due to an altered metabolic situation, higher comorbidity rates and often polypharmacy. Furthermore gerontopsychiatric patients can often not articulate their symptoms clearly, for example due to pronounced cognitive impairment. The aim of the study is to gain valid data of possible adverse drug reaction rates, their potential risk factors and outcome, as well as medical prescription practises. To assess these outcomes an intensive pharmacovigilance-monitoring will be conducted at the five participating study sites. At Baseline demographic data, previous and present disorders, use of drugs, previous and present medication, quality of life, cognitive function, physical examination results, laboratory results and ECG will be assessed. Afterwards patients are visited weekly and screened for possible adverse drug reactions. All adverse drug reactions will be coded in the MedDRA-system. In case of a possible serious adverse drug reaction serum levels of all psychotropic substances applicated will be assessed. Drug combinations will be analysed using an established advanced bioinformatic tool (mediQ). Diagnosis, medication intake and possible adverse drug reactions are documented continually. 2 weeks after discharge from the ward, patients will be contacted by phone to assess catamnestic data.

Residual Effects of Zolpidem Tartrate Extended Release and Eszopiclone Vs Placebo [Completed]

Effects of Discontinuation of Benzodiazepine-derivative Hypnotics on Cognitive and Motor Functions in Elderly Persons [Completed]
Benzodiazepines (BZDs) have been reported to cause negative impacts on motor as well as cognitive functions, which in turn could result in lethal incidents including falls especially in the elderly. This notwithstanding, few trials have evaluated a feasibility and benefits of discontinuing BZD-derivative hypnotics in a systematic manner in this frail population. In this 8-week open-label study, we examined changes in motor and cognitive functions following the discontinuation of BZD hypnotics in older persons. OBJECTIVES & HYPOTHESES 1. Primary Objective The primary objective is to examine the feasibility of discontinuing BZD-derivative hypnotics in older people. 2. Secondary Objectives 1. One of the secondary objectives is to examine the magnitude of discontinuing BZD-derivative hypnotics in the stability of body. 2. Another secondary objective is to examine the magnitude of discontinuing BZD-derivative hypnotics in cognitive function. Hypotheses 1. More than 80% of the participants will complete and tolerate all the study procedures. 2a. Participants will show an improvement in the stability of body. 2b. Participants will show an improvement in the cognitive function globally as well as specifically in attention.

more trials >>


Page last updated: 2017-09-13

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017